Image Place holder

Tawee Tanvetyanon, MD, MPH


Specialty: Medical Oncology
Program: Thoracic Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Moffitt Cancer Center at International Plaza
Overview

Cancer Types Treated: Lung Cancer , Mesothelioma , Thymoma

Dr. Tanvetyanon is a medical oncologist with expertise in thoracic as well as head and neck malignancy. He is specialized in lung cancer and mesothelioma. Services offered include a wide array of clinical trials, immunotherapy programs, and hyperthermic intraperitoneal chemotherapy (HIPEC) for malignant mesothelioma. In addition, Dr. Tanvetyanon is experienced in managing abnormal findings from low-dose CT lung cancer screening. Dr. Tanvetyanon is a health outcomes researcher as well as an epidemiologist. To date, he has published over 30 peer-review articles in medical journals including Journal of Clinical Oncology, Annals of Oncology, Head & Neck and Journal of Thoracic Oncology. His research is geared toward improving the quality of cancer care as well as developing of statistical model to predict outcomes.    

Education & Training

Board Certification:

  • Hematology
  • Internal Medicine
  • Medical Oncology

Fellowship:

  • Loyola University Chicago, Stritch School of Medicine, Illinois - Medical Oncology & Hematology

Residency:

  • Albert Einstein Medical Center at Thomas Jefferson Medical College, Pennsylvania -

Medical School:

  • Chulalongkorn University in Bangkok, Thailand - MD
Participating Trials

CLINICAL TRIAL 17723
Expansion of Enduring Infrastructure to Support Lung Cancer Screening Research
Condition: Thoracic
Intervention:
Open

CLINICAL TRIAL 18431
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention:
Open

CLINICAL TRIAL 18522
A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: MAGE-A10c796T
Open

CLINICAL TRIAL 18398
Novartis Pharmaceuticals trial entitled: A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC)
Condition: Thoracic
Intervention: INC280 (Capmatinib)
Open

CLINICAL TRIAL 18094
A Phase 2 Study of Transarterial Chemoperfusion Treatment with Cisplatin, Methotrexate and Gemcitabine in Patients with Unresectable Pleural Mesothelioma
Condition: Thoracic
Intervention: Gemzar (gemcitabine); cisplatin; gemcitabine; methotrexate
Open

CLINICAL TRIAL 18304
A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
Condition: Thoracic
Intervention: AZD1775; MK-1775 (AZD1775); Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin; paclitaxel
Open

CLINICAL TRIAL 17908
Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Screening Step)
Condition: Thoracic
Intervention: 750009 (Rilotumumab); 765338 (AZD4547); 772256 (Palbociclib); AMG102 (Rilotumumab); AMP-514 (Durvalumab); AZD4547; BMN-673 (Talazoparib); BMS-936558 (Nivolumab); CP-675,206 (tremelimumab); Dexamethasone; Durvalumab; Erlotinib; GDC-0032 (Taselisib); Ipilimumab; MEDI4736 (Durvalumab); Nivolumab; Palbociclib; Rilotumumab; Talazoparib; Tarceva (Erlotinib); Taxotere (docetaxel); Yervoy (Ipilimumab); docetaxel; tremelimumab
Open

CLINICAL TRIAL 17970
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Condition: Thoracic
Intervention: Crizotinib; Not Applicable; Placebo; Xalkori (Crizotinib)
Open

CLINICAL TRIAL 18828
Smartphone-Based Assessment of Patient-Reported Outcomes Related to Receipt of Immunotherapy
Condition: Head & Neck
Intervention:
Open

CLINICAL TRIAL 18999
Early Detection of Cancer Progression: Leveraging Team Science
Condition: Thoracic
Intervention:
Open

CLINICAL TRIAL 18871
A Phase Ii, Open-Label, Multicenter, Single-Arm Study To Investigate TheEfficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage Ib, Ii, Iiia Or Selected Iiib Resectable And Untreated Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq)
Open

CLINICAL TRIAL 18494
A Phase I/II Study of Pembrolizumab and Vorinostat in Patients with Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC
Condition: Thoracic
Intervention: Pembrolizumab (Keytruda); SAHA (Vorinostat); Vorinostat; Zolinza (Vorinostat); suberoylanilide hydroxamic acid (Vorinostat)
Open

CLINICAL TRIAL 18923
A Multi-Center Open-Label Phase 1/2 Study of BGB324 in Combination with Erlotinib in Patients with Stage IIIb or Stage IV Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: BGB324; Erlotinib; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 18811
Randomized, Double-Blind, Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)
Condition: Thoracic
Intervention: ADI-PEG 20; Alimta (Pemetrexed); Paraplatin (carboplatin); Pemetrexed; Placebo; carboplatin; cisplatin
Open

CLINICAL TRIAL 19101
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); BMS-986205; Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19112
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19082
A Phase I/Ib Trial of Pirfenidone Combined with Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Paraplatin (carboplatin); Pemetrexed; Pirfenidone; Taxol (paclitaxel); carboplatin; paclitaxel
Open

CLINICAL TRIAL 19122
A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients with Advanced Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2; Nivolumab; Proleukin (Interleukin-2); TIL; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19293
Phase 1b/2 Study Of VX15/2503 In Combination With Avelumab In Advanced Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Avelumab; MSB00100718C (Avelumab); VX15/2503
Open

CLINICAL TRIAL 19406
Phase I/II Study of Nivolumab and Ipilimumab combined with Nintedanib in Non Small Cell Lung Cancer
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nintedanib; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19302
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an anti-LAG-3 Monoclonal Antibody, alone and in combination with an anti-PD-1 in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: Not Applicable; TSR-033; TSR-042
Open

CLINICAL TRIAL 17969
Randomized Study of Erlotinib vs. Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: Erlotinib; Not Applicable; Placebo; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 17690
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic Dysfunction
Condition: Multiple
Intervention: GSK1120212 (Trametinib); Trametinib
Open

CLINICAL TRIAL 17773
A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4
Condition: Genitourinary
Intervention: ASG-22CE
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-033; TSR-042
Open

CLINICAL TRIAL 18321
Phase I/Ib trial of single agent PBF-509 and in combination with PDR001 for patients with advanced NSCLC
Condition: Thoracic
Intervention: PBF-509; PDR001
Open

CLINICAL TRIAL 17361
A Phase I/IB Trial of MEK162 in Combination with Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
Condition: Thoracic
Intervention: Erlotinib; MEK162; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 19077
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide
Condition: Thoracic
Intervention: Paraplatin (carboplatin); carboplatin; cisplatin; etoposide
Open

CLINICAL TRIAL 19625
A Phase 1b Dose-Escalation Study Of TRC105 In Combination With Nivolumab In Patients With Metastatic Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); Carotuximab; Nivolumab; TRC105 (Carotuximab)
Open

CLINICAL TRIAL 19642
A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
Condition: Thoracic
Intervention: ABT-263 (Navitoclax); AZD9291 (Osimertinib); Navitoclax
Open

CLINICAL TRIAL 19163
Combination Immunotherapy with Ipilimumab and Nivolumab plus a Dendritic Cell based p53 Vaccine (Ad.p53-DC) in patients with relapsed Small Cell Lung Cancer (SCLC)
Condition: Thoracic
Intervention: Ad.p53 DC; BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19580
A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BA3011
Open

CLINICAL TRIAL 19509
A Phase 1/2 Study Of Pegzilarginase (AEB1102, Co-Argi-PEG) In Combination With Pembrolizumab In The Treatment Of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Condition: Thoracic
Intervention: Pegzilarginase; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18844
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors
Condition: Multiple
Intervention: AZD2171 (Cediranib); Cediranib (Recentin); Olaparib (Lynparza)
Open

CLINICAL TRIAL 19569
A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Non-small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: AMP-514 (Durvalumab); BI 1361849; CP-675,206 (tremelimumab); Durvalumab; MEDI4736 (Durvalumab); tremelimumab
Open

CLINICAL TRIAL 19228
A Phase 2, Multi-Center, Open Label Study of NIR178 in Combination with PDR001 in Patients with Selected Advanced Solid Tumors and Non-Hodgkin lymphoma
Condition: Thoracic
Intervention: NIR178; Not Applicable; PDR001
Open

CLINICAL TRIAL 18826
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Condition: Genitourinary
Intervention: ALKS 4230; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 19619
Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination with Osimertinib in Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: AZD9291 (Osimertinib); G1T38; Osimertinib
Open

CLINICAL TRIAL 17971
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Condition: Thoracic
Intervention: Not Applicable
Open

CLINICAL TRIAL 19656
Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Condition: Thoracic
Intervention: Ceritinib (Zykadia); Taxotere (docetaxel); docetaxel
Open

CLINICAL TRIAL 19387
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)
Condition: Thoracic
Intervention: Poziotinib
Open

CLINICAL TRIAL 19694
Phase II Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); IMC-1121B (Ramucirumab); Nivolumab; Ramucirumab
Open

CLINICAL TRIAL 19704
Radiation and Chemotherapy with Ipilimumab followed by Nivolumab for Patients with Stage III Unresectable NSCLC
Condition: Thoracic
Intervention: Alimta (Pemetrexed); BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Paraplatin (carboplatin); Pemetrexed; Taxol (paclitaxel); Yervoy (Ipilimumab); carboplatin; cisplatin; etoposide; paclitaxel
Open

CLINICAL TRIAL 19389
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: JNJ-61186372
Open

CLINICAL TRIAL 19389
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: JNJ-61186372
Open

CLINICAL TRIAL 18612
A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Condition: Head & Neck
Intervention: cisplatin
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Gray JE, Chiappori A, Williams CC, Tanvetyanon T, Haura EB, Creelan BC, Kim J, Boyle TA, Pinder-Schenck M, Khalil F, Altiok S, Devane R, Noyes D, Mediavilla-Varela M, Smilee R, Hopewell EL, Kelley L, Antonia SJ. A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. Cancer Immunol Immun. 2018 Sep. Pubmedid: 30209589. Pmcid: PMC6244998.
  • Chatwal MS, Tanvetyanon T. Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?. Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S208-S210. Pubmedid: 30393603. Pmcid: PMC6193911.
  • Robinson LA, Tanvetyanon T, Grubbs D, Antonia S, Creelan B, Fontaine J, Toloza E, Keenan R, Dilling T, Stevens CW, Sommers KE, Vrionis F. Reply to Dickhoff et al. from authors of 'Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer'. Lung Cancer. 2018 Oct;124:322-323. Pubmedid: 30193907.
  • Maller B, Kaszuba F, Tanvetyanon T. Complete Tumor Response of Tracheal Squamous Cell Carcinoma Following Treatment with Pembrolizumab. Ann Thorac Surg. 2018 Oct. Pubmedid: 30326234.
  • Tanvetyanon T, Keenan RJ. Recovery of lung function after segmentectomy versus lobectomy for early-stage lung cancer. J Thorac Dis. 2018 Jul;10(Suppl 18):S2144-S2146. Pubmedid: 30123544. Pmcid: PMC6072929.
  • Robinson LA, Tanvetyanon T, Grubbs D, Antonia S, Creelan B, Fontaine J, Toloza E, Keenan R, Dilling T, Stevens CW, Sommers KE, Vrionis F. Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer. Lung Cancer. 2018 Aug;122:206-213. Pubmedid: 30032833.
  • Chatwal MS, Tanvetyanon T. Malignant mesothelioma clinical trial combines immunotherapy drugs. Immunotherapy. 2018 Apr;10(5):341-344. Pubmedid: 29473471.
  • Kass KS, Velez-Cubian FO, Zhang WW, Toosi K, Tanvetyanon T, Rodriguez KL, Thau MR, Garrett JR, Moodie CC, Fontaine JP, Toloza EM. Effect of advanced age on peri-operative outcomes after robotic-assisted pulmonary lobectomy: Retrospective analysis of 287 consecutive cases. Geriatr Oncol. 2017 03;8(2):102-107. Pubmedid: 28041970.
  • Tanvetyanon T, Gray JE, Antonia SJ. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?. Expert Opin Biol Ther. 2017 03;17(3):305-312. Pubmedid: 28064556.
  • Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. Onco Targets Ther. 2017;10:4239-4250. Pubmedid: 28919776. Pmcid: PMC5587199.
  • Tanvetyanon T, Creelan BC, Antonia SJ. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer. Expert Rev Anticancer Ther. 2016 Sep;16(9):903-910. Pubmedid: 27488231.
  • Mifsud MJ, Tanvetyanon T, Mccaffrey JC, Otto KJ, Padhya TA, Kish J, Trotti AM, Harrison LB, Caudell JJ. Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high-risk salivary gland carcinomas. Head Neck. 2016 Nov;38(11):1628-1633. Pubmedid: 27098984.
  • Shields PG, Herbst RS, Arenberg D, Benowitz NL, Bierut L, Luckart JB, Cinciripini P, Collins B, David S, Davis J, Hitsman B, Hyland A, Lang M, Leischow S, Park ER, Purcell WT, Selzle J, Silber A, Spencer S, Tanvetyanon T, Tiep B, Tindle HA, Tucker-Seeley R, Urbanic J, Hooper MW, Weksler B, Whitlock CW, Wood DE, Burns J, Scavone J. Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2016 Nov;14(11):1430-1468. Pubmedid: 27799513.
  • Tanvetyanon T, Fisher K, Caudell J, Otto K, Padhya T, Trotti A. Adjuvant chemoradiotherapy versus with radiotherapy alone for locally advanced salivary gland carcinoma among older patients. Head Neck. 2016 Jun;38(6):863-870. Pubmedid: 26340707.
  • Robinson LA, Tanvetyanon T, Springett G, Fontaine J, Toloza E, Hodul P, Pimiento JM, Malafa M. Pulmonary metastasectomy for suspected pancreaticobiliary cancer. J Thorac Cardiovasc Surg. 2016 Jul;152(1):75-82. Pubmedid: 27050555.
  • Tanvetyanon T, Boyle TA. Clinical implications of genetic heterogeneity in multifocal pulmonary adenocarcinomas. J Thorac Dis. 2016 Dec;8(12):E1734-E1738. Pubmedid: 28149626. Pmcid: PMC5227290.
  • Glover JR, Velez-Cubian FO, Zhang WW, Toosi K, Tanvetyanon T, Ng EP, Moodie CC, Garrett JR, Fontaine JP, Toloza EM. Effect of gender on perioperative outcomes after robotic-assisted pulmonary lobectomy. J Thorac Dis. 2016 Dec;8(12):3614-3624. Pubmedid: 28149556. Pmcid: PMC5227215.
  • Tanvetyanon T, Padhya T, McCaffrey J, Kish JA, Deconti RC, Trotti A, Rao NG. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2015 Jun;37(6):840-845. Pubmedid: 24623654.
  • Tanvetyanon T, Lee JH, Fulp WJ, Schreiber F, Brown RH, Levine RM, Cartwright TH, Abesada-Terk G, Kim GP, Alemany C, Faig D, Sharp PV, Markham MJ, Malafa M, Jacobsen PB. Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care. J Oncol Pract. 2015 Jul;11(4):332-337. Pubmedid: 25991639.
  • Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyanon T, Leon ME, Neil Hayes D, Haigentz M, Saba N, Nieva J, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2015 Apr;51(4):376-382. Pubmedid: 25593015. Pmcid: PMC4459134.
  • Jacobsen PB, Lee JH, Fulp W, Siegel EM, Shibata D, Laronga C, Gray J, Tanvetyanon T, Schreiber F, Brown R, Levine R, Cartwright T, Abesada-Terk G, Kim G, Alemany C, Faig D, Sharp P, Markham MJ, Malafa M. Florida Initiative for Quality Cancer Care: Changes in Psychosocial Quality of Care Indicators Over a 3-Year Interval. J Oncol Pract. 2015 01;11(1):e103-e109. Pubmedid: 25352389. Pmcid: PMC4582141.
  • Dilling TJ, Extermann M, Kim J, Thompson LM, Yue B, Stevens CW, Antonia S, Gray J, Williams C, Haura E, Pinder-Schenck M, Tanvetyanon T, Kim S, Chiappori A. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014 Nov;90(4):828-833. Pubmedid: 25216856.
  • Wong J, Koch AL, Deneve JL, Fulp W, Tanvetyanon T, Dessureault S. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience. Ann Surg Oncol. 2014 May;21(5):1480-1486. Pubmedid: 24158467.
  • Gray J, Haura EB, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenk M, Kish JA, Kreahling JM, Lush RM, Neuger AM, Tetteh LF, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer Res. 2014 Mar;20(6):1644-1655. Pubmedid: 24429877. Pmcid: PMC4051132.
  • Rodriguez K, Velez-Cubian F, Zhang WW, Tanvetyanon T, Thau M, Moodie C, Garrett J, Fontaine JP, Robinson L, Toloza E. Effects of pulmonary function and of smoking history on perioperative outcomes after robotic-assisted pulmonary lobectomy: retrospective analysis of 201 consecutive patients. Chest. 2014 Mar;145(3 Suppl):48A. Pubmedid: 24638644.
  • Rao NG, Han G, Greene JN, Tanvetyanon T, Kish JA, De Conti RC, Chuong MD, Shridhar R, Biagioli MC, Caudell JJ, Trotti AM. Effect of prophylactic fluconazole on oral mucositis and candidiasis during radiation therapy for head-and-neck cancer. Pract Radiat Oncol. 2014 Mar;3(3):229-233. Pubmedid: 24674369.
  • Tanvetyanon T, Lee JH, Fulp WJ, Schreiber F, Brown RH, Levine RM, Cartwright TH, Abesada-Terk G, Kim GP, Alemany C, Faig D, Sharp PV, Markham MJ, Malafa M, Jacobsen PB. Changes in the care of non-small-cell lung cancer after audit and feedback: the Florida initiative for quality cancer care. J Oncol Pract. 2014 Jul;10(4):e247-e254. Pubmedid: 24737876.
  • Tanvetyanon T, Creelan BC, Chiappori AA. Current clinical application of genomic and proteomic profiling in non-small-cell lung cancer. Cancer Control. 2014 Jan;21(1):32-39. Pubmedid: 24357739.
  • Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A. Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J Immunother. 2013 Oct;36(8):442-450. Pubmedid: 23994887. Pmcid: PMC3846277.
  • Kumar V, Nath K, Berman CG, Kim J, Tanvetyanon T, Chiappori AA, Gatenby RA, Gillies RJ, Eikman EA. Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings. Clin Nucl Med. 2013 Mar;38(3):175-182. Pubmedid: 23354032. Pmcid: PMC3578161.
  • Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013 Jul;31(19):2404-2412. Pubmedid: 23690416. Pmcid: PMC3691357.
  • May JT, Rao N, Sabater RD, Boutrid H, Caudell JJ, Merchant F, Han G, Padhya TA, McCaffrey JC, Tanvetyanon T, Deconti R, Kish J, McCaffrey TV, Trotti A. Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma. Head Neck. 2013 Dec;35(12):1796-1800. Pubmedid: 23468387.
  • Tanvetyanon T, Finley DJ, Fabian T, Riquet M, Voltolini L, Kocaturk C, Fulp WJ, Cerfolio RJ, Park BJ, Robinson LA. Prognostic factors for survival after complete resections of synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data. Ann Oncol. 2013 Apr;24(4):889-894. Pubmedid: 23136230.
  • Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG. A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Ne. 2012 Nov;10(11):1391-1398. Pubmedid: 23138167. Pmcid: PMC5726232.
  • Salah S, Tanvetyanon T, Abbasi S. Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases: systematic review and analysis of reported cases. Lung Cancer. 2012 Jan;75(1):9-14. Pubmedid: 21864934.
  • Phillips KM, Jim HS, Small BJ, Tanvetyanon T, Roberts WS, Jacobsen PB. Effects of Self-directed Stress Management Training and Home-based Exercise on Stress Management Skills in Cancer Patients Receiving Chemotherapy. Stress Health. 2012 Dec;28(5):368-375. Pubmedid: 22972771.
  • Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen EE. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012 Apr;18(7):2056-2065. Pubmedid: 22241789. Pmcid: PMC5157199.
  • Tanvetyanon T, Corman M, Lee JH, Fulp WJ, Schreiber F, Brown RH, Levine RM, Cartwright TH, Abesada-Terk G, Kim GP, Alemany C, Faig D, Sharp PV, Markham MJ, Bepler G, Siegel E, Shibata D, Malafa M, Jacobsen PB. Quality of care in non-small-cell lung cancer: findings from 11 oncology practices in Florida. J Oncol Pract. 2011 Nov;7(6):e25-e31. Pubmedid: 22379428. Pmcid: PMC3219472.
  • Faul LA, Jim HS, Minton S, Fishman M, Tanvetyanon T, Jacobsen PB. Relationship of exercise to quality of life in cancer patients beginning chemotherapy. J Pain Symptom Manag. 2011 May;41(5):859-869. Pubmedid: 21330097. Pmcid: PMC3779914.
  • Bepler G, Dilling TJ, Wagner H, Hazelton T, Williams C, Chen DT, Greenberg H, Walsh F, Simon G, Tanvetyanon T, Chiappori A, Haura E, Stevens C. Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2011 Mar;6(3):553-558. Pubmedid: 21289520. Pmcid: PMC3839293.
  • Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Mar;28(8):1387-1394. Pubmedid: 20142592. Pmcid: PMC3040065.
  • Tanvetyanon T, Robinson L, Sommers KE, Haura E, Kim J, Altiok S, Bepler G. Relationship between Tumor Size and Survival among Patients with Resection of Multiple Synchronous Lung Cancers. J Thorac Oncol. 2010 Jul;5(7):1018-1024. Pubmedid: 20453687.
  • Tanvetyanon T. Quality-of-care indicators for non-small cell lung cancer. Cancer Control. 2009 Oct;16(4):335-341. Pubmedid: 19910920.
  • Tanvetyanon T, Qin D, Padhya T, McCaffrey J, Zhu W, Boulware D, DeConti R, Trotti A. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg. 2009 Jul;135(7):687-692. Pubmedid: 19620591.
  • Tanvetyanon T, Qin D, Padhya T, Kapoor R, McCaffrey J, Trotti A. Survival outcomes of squamous cell carcinoma arising from sinonasal inverted papilloma: report of 6 cases with systematic review and pooled analysis. Am J Otolaryngol. 2009 Jan;30(1):38-43. Pubmedid: 19027511.
  • Tanvetyanon T, Murtagh R, Bepler G. Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab. J Thorac Oncol. 2009 Feb;4(2):268-269. Pubmedid: 19179909.
  • Tanvetyanon T, Padhya T, McCaffrey J, Zhu W, Boulware D, Deconti R, Trotti A. Prognostic Factors for Survival After Salvage Reirradiation of Head and Neck Cancer. J Clin Oncol. 2009 Apr;27(12):1983-1991. Pubmedid: 19289616.
  • Tanvetyanon T, Eikman EA, Sommers E, Robinson L, Boulware D, Bepler G. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol. 2008 Oct;26(28):4610-4616. Pubmedid: 18824709.
  • Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol. 2008 Oct;3(10):1112-1118. Pubmedid: 18827606. Pmcid: PMC2639211.
  • Tanvetyanon T, Robinson L, Schell M, Strong V, Kapoor R, Coit D, BeplerG. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol. 2008 Mar;26(7):1142-1147. Pubmedid: 18309950.
  • Tanvetyanon T, Bepler G. Beta-carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers: a meta-analysis and evaluation of national brands. Cancer. 2008 Jul;113(1):150-157. Pubmedid: 18429004.
  • Tanvetyanon T. Cetuximab in head and neck cancer. N Engl J Med. 2008 Dec;359(25):2725-2726. Pubmedid: 19102011.
  • Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007 Jul;25(19):2741-2746. Pubmedid: 17602079.
  • Tanvetyanon T, Soares H, Djulbegovic B, Jacobsen P, Bepler G. A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol. 2007 Dec;2(12):1091-1097. Pubmedid: 18090580.
  • Tanvetyanon T. Understanding the uncommon thoracic tumors. Cancer Control. 2006 Oct;13(4):252-253. Pubmedid: 17075561.
  • Tanvetyanon T, Stiff P. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006 Jun;17(6):897-907. Pubmedid: 16547070.
  • Tanvetyanon T, Choudhury A. Severity, risk factors, and physician practices in the management of anemia during concurrent chemoradiation for head and neck carcinoma. Cancer. 2006 Apr;106(7):1554-1559. Pubmedid: 16518817.
  • Tanvetyanon T, Garrity ER, Albain KS. Acute lung injury associated with vinorelbine. J Clin Oncol. 2006 Apr;24(12):1952-1953. Pubmedid: 16622272.
  • Tanvetyanon T, Choudhury AM. Physician practice in the discontinuation of statins among patients with advanced lung cancer. J Palliative Care. 2006;22(4):281-285. Pubmedid: 17263055.
  • Tanvetyanon T. Reply to the article "The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer" by K.P. Weinfurt et al. (Ann Oncol 2005; 16: 579-584). Ann Oncol. 2005 Oct;16(10):1712-1713. Pubmedid: 15972282.
  • Tanvetyanon T, Clark J, Campbell S, Lo S. Neoadjuvant therapy: an emerging concept in oncology. South Med J. 2005 Mar;98(3):338-344. Pubmedid: 15813161.
  • Tanvetyanon T. Treatment of localized lymphoma. N Engl J Med. 2005 Jun;352(23):2449-2451. Pubmedid: 15944432.
  • Tanvetyanon T. Medical costs associated with chiropractic care. Arch Intern Med. 2005 Jun;165(11):1313-1314. Pubmedid: 15956016.
  • Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer. 2005 Jan;103(2):237-241. Pubmedid: 15597384.
  • Tanvetyanon T, Stiff P. Recurrent steroid-responsive pancreatitis associated with myelodysplastic syndrome and transformations. Leuk Lymphoma. 2005 Jan;46(1):151-154. Pubmedid: 15621795.
  • Tanvetyanon T. Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2005 Jan;97(1):70. Pubmedid: 15632382.
  • Tanvetyanon T. Talking about death with dying children. N Engl J Med. 2005 Jan;352(1):91-92. Pubmedid: 15635780.
  • Tanvetyanon T, Elmishad AG, Carbone M. Development of malignant mesothelioma during treatment for prolymphocytic leukemia: is asbestos or simian virus 40 a link?. Anticancer Res. 2005 Jan;25(1B):429-433. Pubmedid: 15816607.
  • Tanvetyanon T, Hines E J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. Cancer. 2005 Apr;103(8):1756-1757. Pubmedid: 15751014.
  • Tanvetyanon T. Molecular prediction of recurrence of breast cancer. N Engl J Med. 2005 Apr;352(15):1605-1607. Pubmedid: 15832454.
  • Tanvetyanon T, Toor A, Stiff P. Post-transplant air-leak syndrome. Br J Haematol. 2004 Sep;126(6):758-758. Pubmedid: 15352978.
  • Nand S, Tanvetyanon T. Proton pump inhibitors and iron deficiency: is the connection real?. South Med J. 2004 Sep;97(9):799. Pubmedid: 15455957.
  • Tanvetyanon T, Stiff P. Second allogeneic transplantation using a reduced-intensity preparative regimen for relapsed myelofibrosis. Am J Hematol. 2004 Oct;77(2):204-205. Pubmedid: 15389913.
  • Tanvetyanon T. Which patient with a do-not-intubate order is a candidate for noninvasive ventilation. Crit Care Med. 2004 Oct;32(10):2148-2150. Pubmedid: 15483429.
  • Tanvetyanon T. Arterial thrombosis in systemic lupus erythematosus. N Engl J Med. 2004 Oct;351(18):1910-1911. Pubmedid: 15515221.
  • Tanvetyanon T, Nand S. Pancytopenia in hereditary haemorrhagic telangiectasia. Brit J Haematol. 2004 Nov;127(4):371. Pubmedid: 15521911.
  • Tanvetyanon T. Re: Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol. 2004 Nov;172(5 Pt 1):2082. Pubmedid: 15540794.
  • Tanvetyanon T. Treatment of von Willebrand's Disease. N Engl J Med. 2004 Nov;351(22):2345-2346. Pubmedid: 15570685.
  • Tanvetyanon T, Choudhury A. Hypocalcemia and azotemia associated with zoledronic acid and interferon alfa. Ann Pharmacother. 2004 Mar;38(3):418-421. Pubmedid: 14970365.
  • Tanvetyanon T. Screening for primary human immunodeficiency virus infection. Arch Intern Med. 2004 Mar;164(6):680-680. Pubmedid: 15037504.
  • Tanvetyanon T, Nand S. Herpes zoster during treatment with arsenic trioxide. Ann Hematol. 2004 Mar;83(3):198-200. Pubmedid: 15064871.
  • Tanvetyanon T. Adjuvant treatment of breast cancer with exemestane. N Engl J Med. 2004 Jul;351(1):100-102. Pubmedid: 15237463.
  • Tanvetyanon T. HER-2 and fluorescent in situ hybridization to evaluate breast cancer. Jama. 2004 Jul;292(3):328. Pubmedid: 15265845.
  • Tanvetyanon T. Telephone psychotherapy and care management for depression. Jama. 2004 Dec;292(22):2720. Pubmedid: 15585725.
  • Tanvetyanon T, Ratanatharathorn V, Leopairat J. Mucoepidermoid carcinoma of the lung presenting as a cavitary lesion. J Med Assoc Thai. 2004 Aug;87(8):988-991. Pubmedid: 15471307.
  • Tanvetyanon T, Choudhury A. Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade. J Urol. 2004 Apr;171(4):1627. Pubmedid: 15017238.
  • Tanvetyanon T. Is hypocalcemia during therapy with zoledronic acid or other bisphosphonates beneficial to cancer patients?. Med Hypotheses. 2004;63(4):764-765. Pubmedid: 15325030.
  • Tanvetyanon T, Stadtmauer EA, Kerson LA. Concurrent administration of interferon alfa-2b and beta-1a. Ann Pharmacother. 2003 Jan;37(1):77-79. Pubmedid: 12503938.
  • Tanvetyanon T, Leighton J. Life-sustaining treatments in patients who died of chronic congestive heart failure compared with metastatic cancer. Crit Care Med. 2003 Jan;31(1):60-64. Pubmedid: 12544994.
  • Tanvetyanon T, Tapaneeyakorn J. Octreotide for bleeding as a result of hepatocellular carcinoma invasion of the gastrointestinal tract. J Gastroenterol Hepatol. 2003 Feb;18(2):231-232. Pubmedid: 12542614.
  • Tanvetyanon T, Nand S. Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing. Ann Pharmacother. 2003 Dec;37(12):1818-1820. Pubmedid: 14632593.
  • Tanvetyanon T, Walkenstein M, Marra A. Inaccurate glucose determination by fingerstick in a patient with peripheral arterial disease. Ann Intern Med. 2002 Nov;137(9):W1-W1. Pubmedid: 12416976.
  • Sirisinha T, Ratanatharathorn V, Jirajarus M, Sirilerttrakul S, Silpakit C, Sirachainan E, Tanvetyanon T. The European Organization for Research and Treatment of Cancer quality of life questionnaire: translation and reliability study of the Thai version. J Med Assoc Thai. 2002 Nov;85(11):1210-1219. Pubmedid: 12546319.
  • Tanvetyanon T, Leighton J. Severe anemia and marrow plasmacytosis as presentation of Sjogren's syndrome. Am J Hematol. 2002 Mar;69(3):233-233. Pubmedid: 11891816.
  • Tanvetyanon T, Dissin J, Selcer U. Hyperthermia and chronic pancerebellar syndrome after cocaine abuse. Arch Intern Med. 2001 Feb;161(4):608-610. Pubmedid: 11252123.
  • Tanvetyanon T, Cohn J. Eligibility for outpatient treatment with low-molecular-weight heparin in venous thromboembolism. Arch Intern Med. 2000 Mar;160(6):869-870. Pubmedid: 10737288.
  • Maller B, Peguero E, Tanvetyanon T. Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma. J Immunother. 41(9):411-412. Pubmedid: 29742520.